Biotech CEO & Investor Conference Fosters Industry Partnership and Growth
This conference is one of the largest life science investor events on the East Coast. The format provides a unique forum where CEOs from small-, medium- and large-cap companies, as well as private companies planning to go public, can interact with investors and other members of the financial community and the health-care industry to promote their research.
Investor sessions hosted by top investment banks and moderated by leading analysts will focus on specific disease areas or discovery technologies. The CEO roundtables will highlight important issues that affect industry growth and company health. CEOs will share their experiences regarding industry consolidation, growth strategies and protection of intellectual property.
Attendees will include biotech company executives, investors and other knowledgeable industry representatives. More than 350 CEOs are expected to participate in the 14 investor sessions, 13 CEO roundtables and more than 94 individual company presentations scheduled during the conference.
“This year’s conference was a remarkable success, drawing more than 1,500 people,” said BIO President Carl B. Feldbaum. “Our event in February is expected to attract an even larger group of investors, biotech leaders and news media. We want many more investors to understand the inherent, fast-growing value of biotechnology, especially in health care. That’s the fundamental goal of BIO’s CEO & Investor Conference,” said Feldbaum.
For more information on the CEO & Investor Conference 2002, please visit www.investinbio.com. Press registration is complimentary for credentialed members of the news media. Press releases, conference updates and registration information are posted in the “Media” section of the conference Web site. Contact Carrie Housman at BIO (202-962-9200) with any questions.
CEO & Investor Conference 2002 sponsors include AstraZeneca; Ferghana Partners, Inc.; Fortis; GATX Ventures, Inc.; JP Morgan H&Q; Lazard Freres & Company, LLC; Lehman Brothers; Palmer & Dodge, LLP; Pricewaterhouse Coopers, LLP; and, Thomas Weisel Partners, LLC.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit our Web site, www.bio.org.